For research & informational purposes only.  Nothing on this site is medical advice or a recommendation to use any compound.

MOTS-c

Mitochondrial open reading frame of the 12S rRNA-c · a mitochondrial-derived peptide
Status: Research only Evidence: Mostly preclinical Route: Injection (in research) Prescription: Not available

What it is

MOTS-c is a tiny 16-amino-acid peptide your own body produces, encoded inside the mitochondria rather than the cell nucleus. It was identified in 2015 and belongs to a small family of "mitochondrial-derived peptides." It is naturally present in blood, and levels appear to decline with age.

Not an approved medicine MOTS-c is not approved for human therapeutic use. It is sold and used as a research chemical. Human clinical data is very limited.

How it works

MOTS-c is involved in metabolism and cellular energy. Skeletal muscle is its main target, where it appears to improve "metabolic flexibility" by activating AMPK, an enzyme central to how cells manage energy. Under stress it can move into the cell nucleus and influence gene expression linked to metabolism. Notably, exercise raises MOTS-c levels in human muscle and blood, which is why it is often described as an exercise-induced peptide.

What the evidence shows

This is where honesty matters. Most of the encouraging findings come from mice, not people.

  • In mice, MOTS-c prevented age-related and diet-induced insulin resistance, and reduced diet-induced obesity.
  • In animal and cell studies it reduced pro-inflammatory markers and improved glucose handling.
  • Human studies so far are mostly observational: they measure natural MOTS-c levels and correlate them with metabolic health and exercise, rather than testing it as a treatment.
The key limitation As of now, MOTS-c has not been robustly tested in humans as an injected therapeutic, and its safety in people has not been thoroughly established. Promising mouse data does not reliably translate to humans.
Human evidence
Very limited
Animal evidence
Encouraging
Regulatory standing
None
Long-term safety data
Minimal

What people study it for

Research interest centres on metabolic health, insulin sensitivity, physical capacity and aging. These are areas of investigation, not proven outcomes in humans. An earlier analog reached an early human trial through a biotech company, but clinical development did not progress to an approved product.

Where it stands

MOTS-c is a genuinely interesting molecule in aging and metabolism research. But it sits firmly in the "research only" category: no approval, scant human safety data, and benefits that remain hypothetical in people. Anything sold under this name is unregulated and of unverified quality.

Research & informational purposes only This page describes scientific research on MOTS-c. It is not a recommendation to obtain or use it.

References

  1. Lee C et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism, 2015. Article
  2. MOTS-c in Human Aging and Age-Related Diseases (review). IJMS, 2022. PMC
  3. Cognitive Vitality profile: MOTS-c. Alzheimer's Drug Discovery Foundation. PDF
  4. Correlation between mitochondrial-derived peptides and metabolic states (meta-analysis), 2024. PMC